Background:
Prostate cancer may return after treatment in 30,000 to 50,000 people each year. There is no clear best way to treat these people. Better treatments are needed.
Objective:
To test a study drug (enzalutamide), both alone and combined with a second drug (PDS01ADC), in people with prostate cancer that returned after treatment.
Eligibility:
People aged 18 years and older with prostate cancer that returned after treatment.
Design:
Participants will be screened. They will have a physical exam, with blood tests. All their urine will be collected for 24 hours. They will have imaging scans of their chest, abdomen, pelvis, and bones. Their ability to perform everyday activities will be assessed. They may opt to give a stool sample.
Participants will be treated in 4-week cycles.
Enzalutamide is a pill taken by mouth once a day, every day. All participants will be given a supply of this drug to take at home.
PDS01ADC is injected under the skin once a month, on the first day of each cycle. Half of the participants will receive both drugs.
All participants will visit the clinic once a month. Each visit should last no more than 8 hours. Blood and urine tests will be repeated.
All participants will receive the study treatment for 3 cycles. Some participants may need 3 more cycles of treatment with enzalutamide only. This re-treatment can be done only once.
Participants will have a follow-up visit 1 month after they finish treatment. After that, they will have visits every 6 weeks for up to 5 years. Imaging scans and blood tests will be repeated.
...

Start Date22 Apr 2024

Sponsor / Collaborator

National Cancer Institute

NCT05361798

/ RecruitingPhase 2IIT

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Background:
Prostate cancer is often treated with radiation and ADT (ADT is androgen deprivation therapy). Up to 30% of these cancers recur within 5 years of treatment. Researchers want to see if a new drug (M9241) can help the immune system to fight prostate cancer.
Objective:
To find what doses of M9241 are safe in people who are treated for prostate cancer. Also, to see what effects M9241 has on the immune system.
Eligibility:
People aged 18 and older with high- and intermediate-risk prostate cancer. Their cancer must not have spread to other parts of the body.
Design:
The study will last 7 months.
Participants will be screened. They will share their medical history. They will also have:
A physical exam
Routine blood and urine tests
Imaging scans of the chest, abdomen, and pelvis
A bone scan
A tumor biopsy
A specialized MRI. Participants will lie face down on the MRI scanner table. An antenna that receives a signal may be placed in the rectum.
All participants will be treated with radiation therapy and ADT.
Some participants will also receive M9241 as an injection under the skin. This treatment will start 4 weeks after the radiation has ended. Participants will receive a total of 3 doses. The injections will be 4 weeks apart. Some screening tests will be repeated at each visit.
Participants who do not receive M9241 will also have screening tests during the treatment period.
Participants will return for follow-up about 1 month after the last treatment or set of tests.

Start Date12 Jun 2023

Sponsor / Collaborator

National Cancer Institute

NCT05286814

/ RecruitingPhase 2IIT

Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Background:
One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment. The drug triggers the immune system to fight cancer.
Objective:
To see if treatment with HAIPs to deliver liver-directed chemotherapy in combination with PDS01ADC is effective for certain cancers.
Eligibility:
People aged 18 and older who have cancer of the bile ducts that is only in the liver, or colorectal cancer that has spread to the liver.
Design:
Participants will be screened with:
Medical history
Physical exam
Blood tests
Pregnancy test (if needed)
Tumor biopsy (if needed)
Electrocardiogram
Computed tomography (CT) scans
Participants will have an abdominal operation. A catheter will be placed into an artery that feeds blood to the liver. The catheter will then be attached to the HAIP. The HAIP will lay under the skin on the left side of the abdomen.
Participants will have chemotherapy drugs or heparin with saline infused into the HAIP every 2 weeks. PDS01ADC will be injected under the skin every 4 weeks. They will get systemic chemotherapy through an IV or mediport every 2 weeks. They will receive this treatment until their cancer gets worse or they have bad side effects.
Participants will have 2 study visits each month. They will have CT scans every 8 weeks. At visits, they will repeat some screening tests.
Participants will have a follow-up visit 1 month after treatment ends. Then they will be contacted every 6 months for 5 years.

Start Date24 Oct 2022

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with NHS-IL-12

100 Translational Medicine associated with NHS-IL-12

100 Patents (Medical) associated with NHS-IL-12

Literatures (Medical) associated with NHS-IL-12

01 May 2025·Journal for ImmunoTherapy of Cancer

Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy

Article

Author: Medina-Enriquez, Miriam Marlene ; Lassoued, Wiem ; Khelifa, Asma S ; Jochems, Caroline ; Gulley, James L ; Gameiro, Sofia R ; Burnett, Daniel ; Lothstein, Katherine E ; Schlom, Jeffrey ; Roller, Nicholas ; Miyamoto, Masaya ; Poppe, Lisa K

Background:

Human papillomavirus (HPV)-associated malignancies continue to present a major health concern despite the development of prophylactic vaccines. Standard therapies offer limited benefit to patients with advanced-stage disease. Despite improved outcomes with programmed cell death protein-1 (PD-1) targeted therapies, treatment resistance and modest response rates highlight a significant unmet need to develop novel therapies for these patients. PDS0101 (designated HPV vaccine) is a liposomal nanoparticle HPV16-specific therapeutic vaccine that has been shown to generate strong HPV-specific responses in preclinical and clinical studies. Here we assess the efficacy of this HPV vaccine in combination with the tumor-targeting immunocytokine NHS-IL12 (PDS01ADC), plus either αPD-1 or the class I histone deacetylase inhibitor Entinostat.

Methods:

Mice bearing HPV16+, αPD-1 refractory TC-1 and mEER tumors were treated with HPV vaccine, NHS-IL12, and either αPD-1 or Entinostat to determine antitumor efficacy and survival benefits. A comprehensive analysis of the tumor microenvironment was performed using flow cytometry, multiplex immunofluorescence, chemokine and cytokine assessment, and single-cell RNA sequencing with T-cell receptor (TCR) enrichment.

Results:

Combination of HPV vaccine and NHS-IL12 with either Entinostat or αPD-1 yielded significant antitumor activity and prolonged survival in αPD-1 refractory models of HPV16+cancer, with superior activity employing Entinostat versus αPD-1 combination. Entinostat triple therapy increased overall and HPV16-specific tumor CD8+T-cell infiltration with heightened cytotoxicity. TCR sequencing revealed a CD8+T-cell clone unique to vaccine-treated cohorts, which displayed an enriched cytotoxic transcriptional profile with triple therapy. These effects were paralleled by strong differentiation of tumor-associated macrophages (TAMs) towards pro-inflammatory, antitumor M1-like cell states. Single-cell transcriptomic analysis indicated all three agents were required for highest modulation of both CD8+T cells and TAMs conducive to tumor control. A biomarker signature reflecting the preclinical findings was found to be associated with improved survival in patients with HPV-associated malignancies.

Conclusion:

Together, these findings provide a rationale for the combination of HPV vaccine, NHS-IL12, and Entinostat in the clinical setting for patients with HPV16-associated malignancies.

01 Apr 2025·JAMA Oncology

Novel Combination Immunotherapy and Clinical Activity in Patients With HPV-Associated Cancers

Article

Author: Strauss, Julius ; Manu, Michell ; Floudas, Charalampos S. ; Steinberg, Seth M. ; Kackley, Mary ; Francis, Deneise C. ; Pastor, Danielle M. ; Krauss, Elizabeth ; Redman, Jason M. ; Manukyan, Manuk ; Marté, Jennifer L. ; Cordes, Lisa M. ; Donahue, Renee N. ; Goswami, Meghali ; Schlom, Jeffrey ; Turkbey, Evrim B. ; Lamping, Elizabeth ; Brownell, Isaac ; Gulley, James L. ; Jochems, Caroline

IMPORTANCE:

Patients who experience progression of advanced human papillomavirus (HPV)–associated cancers and who have previously received first-line systemic treatment have a poor prognosis and limited therapeutic options.

OBJECTIVE:

To assess the clinical activity of the combination of the HPV type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin 12 antibody-drug conjugate PDS01ADC, and the bifunctional anti–programmed cell death ligand 1 (PD-L1)/transforming growth factor β (TGF-β) bintrafusp alfa in advanced HPV-associated cancers.

DESIGN, Setting, and Participants:

This nonrandomized clinical trial was phase 1/2 and investigator initiated, and was conducted at a single US cancer research center between June 2020 and July 2022. Patients with advanced or metastatic HPV-associated cancers were eligible, including patients who were both immune checkpoint blockade (ICB) naive and ICB resistant. The cutoff date for data analysis was May 13, 2024.

INTERVENTION:

Patients received 1 mL of PDS0101 subcutaneously every 4 weeks for 6 doses then every 12 weeks for 2 additional doses, PDS01ADC, 16.8 µg/kg, subcutaneously every 4 weeks or PDS01ADC, 8 µg/kg, subcutaneously every 2 weeks, and bintrafusp alfa, 1200 mg, intravenously every 2 weeks.

MAIN OUTCOMES AND MEASURES:

Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors version 1.1 in ICB-naive patients.

RESULTS:

Of the 50 eligible patients, 26 (52%) were men and the median age was 56 years (range, 28-80 years). The median (IQR) follow-up was 37.7 (30.6-42.0) months. Fourteen patients (28%) were ICB naive, with an ORR of 35.7% (95% CI, 12.8%-64.9%), and median overall survival (OS) 42.4 months (95% CI, 8.3 months-not estimable); in ICB-resistant patients, the ORR was 16.7% (6 of 36 patients; 95% CI, 6.4%-32.8%) and median OS was 15.8 months (95% CI, 9.0-21.3 months). Among patients with HPV-16–positive tumors (37 patients [74%]), in the ICB-naive group (8 patients [21.6%]) the ORR was 62.5% (95% CI, 24.5%-91.5%) and a median OS measure was not reached. Grade 3 and 4 treatment-related adverse events occurred in 26 of 50 patients (52%). There were no treatment-related deaths.

CONCLUSIONS AND RELEVANCE:

In this trial, the combination of PDS0101, PDS01ADC, and bintrafusp alfa showed an acceptable safety profile and promising antitumor activity and improved OS in patients with HPV-16–positive cancers, in both ICB-naive and ICB-resistant patients, warranting further evaluation of the combination of PDS0101 and PDS01ADC with simultaneous PD-L1/TGF-β inhibition in these populations.

Trial Registration:

ClinicalTrials.gov Identifier: NCT04287868

01 Jun 2024·Journal of Gastrointestinal Oncology

Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: a phase II trial protocol

Article

Author: Rainey, Ashley J ; Hannah, Cathleen E ; Eade, Alyssa V ; Smith, Kathleen M ; Pu, Tracey ; Blakely, Andrew M ; Hernandez, Jonathan M ; Smith, Emily C ; Davis, Jeremy L ; Luberice, Kenneth ; Xie, Changqing ; Friedman, Lindsay R ; Greten, Tim F ; Gulley, James L ; Monge, Cecilia ; Ramamoorthy, Bhavishya ; Victory, Jack H ; Lambdin, Jacob ; Larrain, Carolina ; Mabry, Donna ; Schlom, Jeffrey ; Sarvestani, Amber Leila ; Ryan, Carrie E

Background:

Treatment of advanced liver tumors remains challenging. Although immune checkpoint inhibition has revolutionized treatment for many cancers, responses in colorectal liver metastases and biliary tract cancers remain suboptimal. Investigation into additional immunomodulatory therapies for these cancers is needed. Interleukin-12 (IL-12) is a pro-inflammatory cytokine with robust anti-tumor activity, but systemic adverse effects largely terminated therapeutic development of recombinant human IL-12 (rhIL-12). PDS01ADC is a novel human monoclonal antibody (NHS76) conjugated to two IL-12 heterodimers with established safety in phase I trials. The NHS76 antibody specifically targets histone/DNA complexes which are accessible only in regions of cell death and this antibody has been shown to accumulate locally in tumors.

Methods:

Patients with unresectable metastatic colorectal cancer (mCRC) or unresectable intrahepatic cholangiocarcinoma (ICC) will receive synchronization of subcutaneous PDS01ADC with floxuridine delivered via a hepatic artery infusion pump (HAIP). The primary outcome measured in this study will be overall response rate as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Secondary outcomes measured in this study will include hepatic and non-hepatic progression-free survival (PFS), overall survival, and safety of PDS01ADC combination therapy with HAIP.

Discussion:

Poor clinical response of these liver tumors to immunotherapy is likely due to various factors, including poor immune infiltrate into the tumor and immunosuppression by the tumor microenvironment. By exploiting the tumor cell death induced by HAIP locoregional therapy in combination with systemic chemotherapy, PDS01ADC is poised to modulate the tumor immune microenvironment to improve outcomes for patients undergoing HAIP therapy.

Trial Registration:

ClinicalTrials.gov (ID NCT05286814 version 2023-10-18); https://clinicaltrials.gov/study/NCT05286814?term=NCT05286814&rank=1.

News (Medical) associated with NHS-IL-12

02 Jun 2025

·www.globenewswire.com

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Median overall survival data in first-line recurrent/metastatic (1L r/m) HNSCC remains durable at 30.0 months with additional follow-up of ~4.5 months beyond the initial abstract HPV16-positive is the most rapidly increasing HNSCC in the US VERSATILE-003 is the only ongoing Phase 3 clinical trial exclusively addressing 1L r/m HPV16-positive HNSCC PRINCETON, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced publication of three Versamune® HPV abstracts now available on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. These abstracts summarize Versamune® HPV (PDS0101) studies that were presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois. It is estimated that over 50% of head and neck squamous cell carcinoma (HNSCC) cases in the US are HPV16-positive.1 HPV-positive and HPV-negative HNSCC are two distinct diseases with different underlying causes, origin, risk factors, and contributions to the development of HNSCC. Multiple types of HPV are associated with HSNCC, and those cases are commonly identified with a p16 histochemistry test and referred to as p16-positive. A p16-positive test result suggests that the patient’s cancer may be due to any of the over 100 types of HPV. PDS Biotech is specifically addressing HNSCC related to HPV type 16 (HPV16), the most carcinogenic type of HPV. 2 HPV16-positive HNSCC has been identified as a rapidly growing and severe medical need.3,4 HPV16 is a specific type of HPV that must be confirmed using a polymerase chain reaction (PCR) test. PDS Biotechnology’s trial differs from the other ongoing Phase 3 clinical trials addressing 1L r/m HNSCC based on its specific HPV16-positive HNSCC target population and its therapeutic approach. Phase 3 DevelopmentEGFR Bispecific AntibodiesPDS BiotechnologyTherapeutic ApproachBlocking antibodies targeting EGFR and a second receptorHPV16-targeted T cell immunotherapyTreated PopulationsPredominantly HPV-negative and no confirmed HPV16-positive HNSCC patients#100% HPV16-positive HNSCC*Mechanism of ActionInhibition of EGFR signaling and either LGR5 or TGF-βPromotes multi-functional CD4 (helper) and CD8 (killer) T cell response targeting HPV16 E6 and E7 expressing tumors #P16 histochemistry test to determine infection with any of > 100 types of HPV*Confirmatory PCR test for HPV16-positive specific infection Kevin Harrington, M.D., Ph.D. of The Institute of Cancer Research in the United Kingdom stated, “HPV-positive HNSCC is today seen as a different disease from HPV-negative HNSCC. HPV-positive HNSCC has different biological characteristics and requires a more targeted approach that treats the underlying HPV integration and persistence into the patient’s tumor DNA. Cytotoxic drugs and the EGFR inhibitor cetuximab have not worked as well in HPV-positive HNSCC to date.” HPV16 has been reported to suppress the immune system’s ability to respond to the virus, resulting in more difficult-to-treat and non-immunogenic tumors.5 At least two studies have compared patients with HPV16-positive HNSCC with p16-positive patients (excluding HPV16) and patients with HPV-negative HNSCC, and shown patients with HPV16-positive HNSCC to have significantly worse survival prognosis than other p16-positive HNSCC, and in an advanced oral cancer study, patients with HPV16-positive HNSCC had significantly worse survival than patients with HPV-negative HNSCC.6,7 To accurately identify and appropriately treat patients with HPV16-positive HNSCC, the U.S. Food and Drug Administration (FDA) recommended that a companion diagnostic be developed and included in the ongoing VERSATILE-003 Phase 3 trial. VERSATILE-002: Overall Survival of HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated with T Cell Stimulating Immunotherapy PDS0101 and Pembrolizumab (Abstract #6037) - Poster Presentation. June 2, 2025, 9:00 a.m.-12:00 p.m. CDT The trial was performed across 31 sites in the US and Europe. Median follow-up time is 22.1 months (range 0.2-43.0 months), representing one of the most extended follow-up periods to date of subjects receiving treatment for HPV16-positive 1L r/m HNSCC. Median overall survival (mOS) has remained steady at 30.0 months over the last 1.5 years, suggesting durability of the Versamune® HPV-induced clinical responses. The lower limit of the 95% confidence interval for mOS has, however, increased from 18.4 months in 2023 to 23.9 months as the data has matured. All data are reported according to RECISTv1.1 criteria, requiring clinical responses on at least two consecutive tumor scans at least 4 weeks apart. Enrollment in the trial (n=53) is complete; 22 patients (including 3 still on treatment) continue to be followed for survival. No new safety signals have emerged. Summary of results for Versamune® HPV with pembrolizumab stratified by patient CPS status. Versamune® HPV (PDS0101) + Pembrolizumab (VERSATILE-002) CPS ≥ 1N=53 (100%)CPS ≥ 20N=21/53 (40%)CPS 1-19N=32/53 (60%)Median Overall Survival (mOS)30.0 months(95% Confidence interval, lower limit of 23.9 months, upper limit not yet estimable (NE))39.3 months(95% CI 30.0, NE)26.1 months(95% CI 15.3, NE)Median Progression Free Survival (PFS)6.3 months(95% CI 2.8, 14.1)14.1 months(95% CI 2.1, NE)5.1 months(95% CI 2.2, 8.1)Objective Response Rate (ORR)19/53 (35.8%)10/21 (47.6%)9/32 (28.1%)Tumor Shrinkage of 90-100%11/53 (20.8%)6/21 (28.6%)5/32 (15.6%)Disease Control Rate (DCR)41/53 (77.4%)17/21 (81.0%)24/53 (75.0%)Median Duration of Response (DoR)21.8 months(95% CI 11.5, NE)NE(95% CI 5.6, NE)21.8 months(95% CI 4.2, NE) The longest published mOS reported to date with pembrolizumab monotherapy and combinations with pembrolizumab in patients with 1L r/m HNSCC and CPS ≥ 1 is 17.9 months8. Jared Weiss, M.D., Section Chief of Thoracic and Head/Neck Oncology, Professor of Medicine at the University of North Carolina, and Principal Investigator of the VERSATILE-002 Phase 2 clinical trial, stated, “The mOS results are highly encouraging in patients with advanced HPV Type 16-positive HNSCC. This is great news for patients, and we are encouraged that mOS has remained durable over the last 1.5 years. We look forward to the randomized Phase 3 trial, which is the only ongoing registrational trial to specifically address this rapidly growing population of patients.” Dr. Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech, continued, “We are very pleased with the overall survival (OS) results. As stated in a 2023 Journal of Clinical Oncology article authored by the FDA, OS is considered the gold standard for oncology approvals. The article discussed the discordance between ORR, PFS and OS. In recently published registrational 1L r/m HNSCC studies, improved ORR and PFS have not translated to improved OS. We look forward to the two interim survival data readouts from the ongoing Phase 3 study as well as the final OS results.” 1 November 2024. Company sponsored independent third-party primary market research.2 Nelson CW and Mirabello L, 2023, Tumor Virus Research, 15 200258 3 Damgacioglu H et al; The Lancet Regional Health – Americas. 2022;8:100143.4 Gormley L et al; British Dental Journal, Vol. 233 (9), Nov. 11 2022.5 Luo X et al; J Clin Invest. 2020;130(4):1635–1652.6 Journal for ImmunoTherapy of Cancer 2022;10:e005158. doi:10.1136/ jitc-2022-005158. 7 Lee LA et al, 2012, PLoS ONE 7(7): e40767. doi:10.1371/journal.pone.0040767.8 Licitra L et al; Int. J. Radiation Oncology, April 01 2024, Volume 118, Issue 5e2-e3 About PDS Biotechnology PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. For more information, please visit www.pdsbiotech.com Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune® HPV, PDS01ADC and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune® HPV, PDS01ADC and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.   Versamune® is a registered trademark of PDS Biotechnology Corporation. Investor Contact:Mike MoyerLifeSci AdvisorsPhone +1 (617) 308-4306 Email: mmoyer@lifesciadvisors.com Media Contact:Janine McCargo6 DegreesPhone +1 (646) 528-4034Email: jmccargo@6degreespr.com

ImmunotherapyPhase 3ASCOPhase 2Clinical Result

22 May 2025

·www.einpresswire.com

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Phase 2: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Median overall survival for CPS ≥20 is 39.3 months - Median overall survival for CPS ≥1 is 30.0 months Phase 3: Versamune ® HPV with pembrolizumab as 1L treatment of r/m HPV16-positive HNSCC - Trial-in-progress currently enrolling patients Conference call on Friday, May 23 at 8:00 a.m. ET to discuss ASCO abstract data sets PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced publication of three Versamune ® HPV abstracts now available on the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting website. These abstracts summarize Versamune ® HPV (PDS0101) studies to be presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois. Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech stated, “We continue to be excited about the strength and durability of the VERSATILE-002 data showing the longest survival reported to date in 1L recurrent/metastatic (r/m) head and neck cancer (HNSCC). These results further strengthen our confidence in the ongoing VERSATILE-003 trial, which is the only registrational trial for the rapidly growing population of patients with HPV16-positive r/m HNSCC. Based on our estimates 1 , HPV16-positive patients are as likely to progress to recurrent and/or metastatic stage as HPV-negative patients, and HPV16-positive patients currently comprise 40-60% of patients in the ICI-naïve r/m HNSCC population in the US.” VERSATILE-002: Overall Survival of HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated with T Cell Stimulating Immunotherapy PDS0101 and Pembrolizumab ( Abstract #6037 ) - Poster Presentation. June 2, 2025, 9:00 a.m.-12:00 p.m. CDT Enrollment in the trial (n=53) is complete; 23 patients (including 3 still on treatment) continue to be followed for survival. No new safety signals have emerged Survival Results: 39.3 months mOS in patients with CPS ≥ 20 (95% Confidence interval, lower limit of 18.4 months, upper limit net yet estimable (NE)); published mOS for pembrolizumab is approximately 15 months 30.0 months mOS (95% CI 23.9, NE) in patients with CPS ≥ 1; published result for pembrolizumab is approximately 12 months 29.5 months mOS (95% CI 15.3, NE) in patients with CPS 1-19; published result for pembrolizumab is approximately 10 months Median follow up of 18.4 months (range 0.2-42.7 months) represents one of the most extended follow-up periods to date of subjects receiving a therapy for HPV16-positive r/m HNSCC. Jared Weiss, M.D., Section Chief of Thoracic and Head/Neck Oncology, Professor of Medicine at University of North Carolina, and Principal Investigator of the VERSATILE-002 Phase 2 clinical trial, will present the poster. VERSATILE-003: A Phase 3, Randomized, Open-label Trial of PDS0101 and Pembrolizumab compared with Pembrolizumab for First-Line Treatment of Patients with HPV16-positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma ( Abstract #TPS6111 ) - Poster Presentation. June 2, 2025, 9:00 a.m.-12:00 p.m. CDT Highlights study objectives and design of the ongoing VERSATILE-003 ( NCT06790966 ) trial Median overall survival is primary endpoint – 2 interim readouts planned 351 patients to be accrued in 2:1 randomization Katharine Price, M.D., Associate Professor of Oncology, Head and Neck Disease Group, Mayo Clinic Comprehensive Cancer Center, and Principal Investigator of the VERSATILE-003 clinical trial, will present the poster. Initial results of MC200710 investigating therapeutic vaccine (PDS0101) alone or with pembrolizumab prior to surgery or radiation therapy for locally advanced HPV associated oropharyngeal carcinoma, a Phase 2 window of opportunity trial ( Abstract #6061 ) - Poster Presentation. June 2, 2025, 9:00 a.m.-12:00 p.m. CDT In the prospective Phase 2 trial, newly diagnosed patients were administered two (2) cycles of Versamune ® HPV alone or in combination with pembrolizumab before surgical resection or chemoradiotherapy (CRT). Results: Clinical activity was seen with only 2 cycles of Versamune ® HPV alone and with 2 cycles of Versamune ® HPV with pembrolizumab 70% of patients who received Versamune ® HPV alone had stable disease 100% of patients who received Versamune ® HPV with pembrolizumab had stable disease or partial response The combination of Versamune ® HPV and pembrolizumab met the trial’s primary endpoint of 50% reduction in circulating tumor DNA (ctDNA) response. David M. Routman, M.D., Assistant Professor of Radiation Oncology, Department of Radiation Oncology, Mayo Clinic, will present the poster. Conference Call Details Date: May 23, 2025 Time: 8:00 a.m. Eastern Time Dial-in: 1-877-704-4453 (Domestic); 1-201-389-0920 (International) Webcast Registration: Click Here Call Me TM Registration: Click Here 1 N ovember 2024 . C ompany sponsored independent third-party primary market research . About PDS Biotechnology PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune ® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. For more information, please visit www.pdsbiotech.com Forward Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune ® HPV, PDS01ADC and other Versamune ® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune ® HPV, PDS01ADC and other Versamune ® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Versamune ® is a registered trademark of PDS Biotechnology Corporation. Investor Contact: Mike Moyer LifeSci Advisors Phone +1 (617) 308-4306 Email: mmoyer@lifesciadvisors.com Media Contact: Janine McCargo 6 Degrees Phone +1 (646) 528-4034 Email: jmccargo@6degreespr.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultImmunotherapyPhase 2ASCOPhase 3

14 May 2025

·www.globenewswire.com

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a clinical and corporate update and reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 and recent weeks have been productive for PDS Biotech, highlighted by the initiation of our VERSATILE-003 Phase 3 clinical trial evaluating Versamune® HPV in recurrent/metastatic (“R/M”) HPV16-positive head and neck squamous carcinoma (“HNSCC”),” said Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotech. “We are pleased to announce that site activation is progressing, and that Mayo Clinic sites have recently been added to the trial. HPV16-positive HNSCC represents a large, rapidly growing patient population in need of targeted therapies to treat the underlying cause of the cancer, and our Versamune® HPV investigational therapy is currently the only targeted therapy in a Phase 3 trial specifically for HPV-16 positive tumors.” Clinical and Corporate Update On April 23, 2025, the Company announced that three abstracts on Versamune® HPV (PDS0101) were selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 30-June 3, 2025, in Chicago, IL.On May 8, 2025, the Company announced that preclinical efficacy and immune response data with a novel investigational Infectimune® based universal flu vaccine were featured in two presentations on universal influenza vaccines, including an oral symposium at the American Association of Immunologists’ IMMUNOLOGY2025™ Annual Meeting, held May 3-7, 2025, in Honolulu, Hawaii.On March 13, 2025, the Company announced U.S. Food and Drug Administration (“FDA”) clearance of an Investigational New Drug (“IND”) application for the combination of Versamune® MUC1 and PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma in patients who failed previous treatment. The National Cancer Institute (“NCI”), under its Cooperative Research and Development Agreement (“CRADA”), will lead the Phase 1/2 clinical trial evaluating the combination of Versamune® MUC1 + PDS01ADC in recurrent/metastatic colorectal cancer.On March 7, 2025, the Company announced the initiation of its VERSATILE-003 Phase 3 trial in HPV16-positive first-line recurrent and/or metastatic HNSCC. Trial is designed to include approximately 350 patientsPDS Biotech is aligned with the FDA on the design of the registrational trial and clinical endpoints. Two-arm controlled trial with 2:1 randomizationMedian overall survival is the primary endpointInterim readouts included in the study design The Company received FDA Fast Track designation for the combination of Versamune® HPV and pembrolizumab in R/M HNSCC.For more information on VERSATILE-003, visit ClinicalTrials.gov (Identifier: NCT06790966). On February 27, 2025, the Company announced that it had entered into securities purchase agreements with new and existing healthcare-focused institutional investors, as well as participation from certain directors of the Company, for the purchase and sale of 7,330,121 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules at a combined purchase price of $1.50 for the institutional investors and $1.66 for certain directors of the Company. Approximately $11 million was funded upon the closing of the offering, and up to an additional $11 million may be funded upon full cash exercise of the warrants. First Quarter 2025 Financial Results Reported net loss was approximately $8.5 million, or $0.21 per basic and diluted share, for the three months ended March 31, 2025, compared to $10.6 million, or $0.30 per basic share and diluted share, for the three months ended March 31, 2024. The decrease was due to increased benefit from income taxes and lower operating expenses. Research and development expenses were $5.8 million for the three months ended March 31, 2025, compared to $6.7 million for the three months ended March 31, 2024. The decrease was primarily due to lower clinical trial expenses. General and administrative expenses were $3.3 million for the quarter ended March 31, 2025, compared to $3.4 million for the three months ended March 31, 2024. Total operating expenses were $9.1 million for the quarter ended March 31, 2025, compared to approximately $10.1 million for the three months ended March 31, 2024. Net interest expenses were $0.6 million compared to approximately $0.5 million for the three months ended March 31, 2024. The Company’s cash balance as of March 31, 2025 was $40 million, compared to $41.7 million as of December 31, 2024. Conference Call Details Date: May 14, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)Webcast Registration: Click HereCall Me™ Registration: Click Here (Available 15 minutes prior to call) About PDS BiotechnologyPDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. For more information, please visit www.pdsbiotech.com Forward-Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to conduct clinical trials for Versamune® HPV, PDS01ADC, Versamune® MUC1 and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune® HPV, PDS01ADC, Versamune® MUC1 and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation. Investor Contact:Mike MoyerLifeSci AdvisorsPhone +1 (617) 308-4306 Email: mmoyer@lifesciadvisors.com Media Contact:Janine McCargo6 DegreesPhone +1 (646) 528-4034Email: jmccargo@6degreespr.com ---financial tables to follow--- PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARYCondensed Consolidated Statements of Operations and Comprehensive Loss(Unaudited) Three Months Ended March 31, 2025 2024 Operating expenses: Research and development expenses $5,830,999 $6,704,164 General and administrative expenses 3,274,759 3,393,463 Total operating expenses $9,105,758 $10,097,627 Loss from operations $(9,105,758) $(10,097,627) Interest income (expense) Interest income $377,849 $668,895 Interest expense (930,878) (1,174,745)Interest income (expense), net $(553,029) $(505,850) Loss before income taxes $(9,658,787) $(10,603,477)Benefit for income taxes 1,169,820 - Net loss and comprehensive loss $(8,488,967) $(10,603,477) Per share information: Net loss per share, basic and diluted $(0.21) $(0.30)Weighted average common shares outstanding basic and diluted 40,521,001 34,815,870 PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARYSelected Balance Sheet Data(Unaudited) March 31, December 31, 2025 2024 Cash and cash equivalents $39,978,674 $41,689,591 Working capital $28,474,112 $27,967,242 Total assets $47,028,542 $45,358,657 Long term debt $6,352,333 $9,204,755 Accumulated deficit $(190,599,966) $(182,110,999)Total stockholders’ equity $22,362,209 $19,004,848

Phase 3ImmunotherapyASCOFinancial StatementFast Track

100 Deals associated with NHS-IL-12

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Prostate Carcinoma	Phase 2	United States	National Cancer Institute	22 Apr 2024
Localized Prostate Carcinoma	Phase 2	United States	National Cancer Institute	12 Jun 2023
HPV-related carcinoma	Phase 2	North America	PDS Biotechnology Corp.	03 Jan 2023
Adrenocortical Carcinoma	Phase 2	United States	National Cancer Institute	24 Oct 2022
Intrahepatic Cholangiocarcinoma	Phase 2	United States	National Cancer Institute	24 Oct 2022
Metastatic Colorectal Carcinoma	Phase 2	United States	National Cancer Institute	24 Oct 2022
Advanced cancer	Phase 2	United States	National Cancer Institute	05 Oct 2021
Colonic Cancer	Phase 2	United States	National Cancer Institute	05 Oct 2021
Vagina Carcinoma	Phase 2	United States	National Cancer Institute	05 Oct 2021
Metastatic Pancreatic Cancer	Phase 2	United States	National Cancer Institute	15 Jun 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04287868 (Company_Website \| Pubmed) Manual	Phase 1/2	HPV-related carcinoma HPV16-positive	50	PDS0101 + PDS01ADC + bintrafusp alfa (BA) (ICB naïve patients)	feborkrzjf(mhmnzkluwj) = zlbonfecjg romimculee (zbgnwhijko, 8.3 - NE) View more	Positive	26 Feb 2025
				PDS0101 + PDS01ADC + bintrafusp alfa (BA) (ICB naïve patients + HPV16-positive)	feborkrzjf(mhmnzkluwj) = yqiyjvilhs romimculee (zbgnwhijko, 9.0 - 21.3) View more
NCT02994953 (COMBO \| JAVELIN IL-12, CTgov)	Phase 1	Locally Advanced Malignant Solid Neoplasm	52	Avelumab+M9241 (Part A Cohort 1: M9241 4 mcg/kg + Avelumab 10 mg/kg)	yxfvfxrogl = vechbptofo tchwasfxyw (mcgcyneias, acqidvszcq - ecfprucrwi) View more	-	20 Sep 2024
				Avelumab+M9241 (Part A Cohort 2: M9241 8 mcg/kg + Avelumab 10 mg/kg)	yxfvfxrogl = ctbmhopjdm tchwasfxyw (mcgcyneias, jqdympolzv - akeqdlslju) View more
NCT04491955 (CTgov)	Phase 2	Colorectal Cancer \| Small intestine carcinoma	32	NHS-IL12 (M9241) (Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241))	tjylayykur = xovgrsepza trdsgdnaws (tuaxrvyjlr, fhffbpadvo - jwfsohxkpg) View more	-	14 Nov 2023
				Fowlpox (FPV)-CV301+N-803+MVA-BN-CV301+M7824+NHS-IL12 (M9241) (Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation)	tjylayykur = xbqjkhcgor awmvcnylpt (riihuzzaoi, penxqwvfzk - uctugfzacy) View more
NCT04287868 (GlobeNewswire) Manual	Phase 2	Human Papillomavirus-16 Positive	-	PDS0101+PDS0301+Bintrafusp-alfa (ICI naïve group)	rslleqspoq(gappzzboki) = ivwrbbstyh jnbzgjvqxy (dnmzlxmisr ) View more	Positive	09 Nov 2023
				PDS0101+PDS0301+Bintrafusp-alfa (ICI resistant group)	rslleqspoq(ufvbsaazcz) = ndyqnhqcxi pvcfmzaznr (nmuvsrzhca ) View more
NCT04235777 (ASCO 12023 \| ASCO 22023) Manual	Phase 1	Urogenital Neoplasms	16	Bintrafusp alfa+M9241	fvfmkykbap(qjyijokvyn) = The most frequent TRAEs were fatigue (grade 2, 38%), lipase increase (grade 2+3, 31%), and anemia (grade 2+3, 31%). Grade 3 hematuria occurred in 2 patients (13%); a grade 4 creatinine increase occurred in one (8%). aqonljrhrl (fcbadcpggw )	Positive	26 May 2023
				SBRT+Bintrafusp alfa+M9241 (bintrafusp alfa and M9241 with either sequential SBRT)
NCT04491955 (ASCO_GI2023) Manual	Phase 2	Advanced Colorectal Adenocarcinoma \| Small intestine carcinoma Second line	30	overall	nnotczkvao(damjkrajlc) = lhalgbcbtd hqkeiawdmp (fbxgmbhkna )	Positive	24 Jan 2023
				CV301+N-803+bintrafusp alfa (triple therapy)	kqcjohpwoe(lahvmvljgf) = mzphwihlsb lshakollhx (arwrrluczs, 33.7 - 86.0) View more
NCT04287868 (ASCO2022) Manual	Phase 2	HPV-related carcinoma HPV Positive	30	M9241+bintrafusp alfa+PDS0101 (with checkpoint naïve disease)	fzvxdljvat(ylxpovosmv) = vutqmnageq qelknnrmhm (ukikmmvvln ) View more	Positive	02 Jun 2022
				M9241+bintrafusp alfa+PDS0101 (with checkpoint refractory disease)	fzvxdljvat(ylxpovosmv) = zimlyvzcng qelknnrmhm (ukikmmvvln ) View more
SITC2019	Not Applicable	-	-	Entinostat	atucdrqtyp(gyvoypasqm) = areas of tumor necrosis identified via H&E staining also displayed DNA fragmentation measured by the TUNEL assay djzzlkjviw (aurqdaqyvi ) View more	Positive	01 Nov 2019
NCT02994953 (JAVELIN IL-12, ESMO2019) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	-	Avelumab+M9241	vyrcxdunxz(mizlpjfsos) = 1 pt (DL3, grade 3 autoimmune hepatitis) dsumlvbpxs (bxaubmevan ) View more	Negative	30 Sep 2019
NCT01417546 (Pubmed \| Clin Cancer Res) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	-	NHS-IL-12	fisrjlmzfm(yvozdhuhox) = No observed mshqkyjcuy (fmetqdmkgc ) View more	Positive	15 Jun 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

NHS-IL-12

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation